BROWN RUDNICK LLP for APOTEX CORPORATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN | Prof Staff, House Cmte on Ed & Workforce 99-01 |
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.